Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2024-02-20 Delisting Announcement
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Delisting Announcement Classification · 1% confidence The document is an official announcement titled "PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market." This explicitly states the company's intent to cease trading on a major exchange (Nasdaq) and details the process, including filing Form 25 and Form 15F with the SEC. This action directly relates to the company's stock listing status and capital structure management, but the core subject is the cessation of trading/delisting. The definition for Delisting Announcement (DLST) is: "Official notice that the company's stock will be removed from an exchange." This document perfectly matches that description, as it is the formal notice of the intention to delist.
2024-02-20 English
PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market
Delisting Announcement Classification · 1% confidence The document is a press release from PHAXIAM Therapeutics announcing its intention to voluntarily delist its American Depositary Shares (ADS) from the Nasdaq Capital Market, while remaining listed on Euronext Paris. The core subject is the cessation of trading on a specific exchange and the associated administrative steps (filing Form 25F and 15F with the SEC to deregister). This action directly relates to the company's stock market status and exchange listing. Among the provided codes, 'DLST' (Delisting Announcement) is the most appropriate classification for an official notice of intent to delist from a major exchange.
2024-02-20 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2024" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of January 31, 2024). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers). The content is a table showing the total number of shares and voting rights for two specific dates (Dec 31, 2023, and Jan 31, 2024). This type of mandatory monthly disclosure regarding the total share capital and voting rights structure is typically classified as a regulatory filing or a specific capital/share structure update. Given the options, it most closely aligns with a notification about the share structure, which is often captured under 'Share Issue/Capital Change' (SHA) if it reflects a change, or sometimes under 'Regulatory Filings' (RNS) if it's a standard periodic disclosure not covered elsewhere. However, since it details the total number of shares and voting rights, it is a direct notification about the capital structure. While 'SHA' covers changes, this is a mandatory periodic report on the current state of shares/voting rights. In many classification schemes, periodic reports on share capital structure fall under a specific capital category. Given the options, 'SHA' (Share Issue/Capital Change) is the closest fit for mandatory reporting on the total number of shares and voting rights, even if no change occurred in the last month, as it pertains directly to the capital base. Alternatively, 'RNS' (Regulatory Filings) is a strong fallback. Since the core subject is the composition of the capital and voting rights, I will classify it as 'SHA' as it is a specific capital structure report, although it is a monthly update rather than a transaction announcement.
2024-02-06 French
Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024" and explicitly references Article 223-16 of the French AMF general regulation. It provides a table detailing the total number of shares and voting rights as of the end of December 2023 and January 2024. This content directly relates to the calculation and reporting of voting rights, which aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA) category, as it reports the current state of voting rights, even if it's a monthly update rather than post-meeting results. It is not a general regulatory filing (RNS) because it fits a specific category (DVA). It is not a proxy statement (PSI) as it reports results/status, not solicitation materials.
2024-02-06 English
PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024
Capital/Financing Update Classification · 1% confidence The document is titled "PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024" (PHAXIAM Therapeutics announces its cash position as of year-end 2023 and its 2024 financial calendar). It provides an update on the cash position as of December 31, 2023, and outlines the schedule for future financial communications (Q4 2023 results release, Q1 2024 results release, etc.) and the date of the Annual General Meeting (AGM). Since it is an announcement detailing key financial highlights (cash position) and scheduling future earnings releases, it strongly aligns with the definition of an Earnings Release (ER), which typically covers the most recent period's key figures before the full report. Although it mentions the AGM date, the primary focus is the financial update and calendar. It is not the full Annual Report (10-K) or a comprehensive Interim Report (IR). It is a press release announcing key financial metrics and future dates.
2024-01-18 French
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
Report Publication Announcement Classification · 1% confidence The document is titled "PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024". It provides a cash update as of December 31, 2023, and lists future events, including updates on Q4 2023 financial data, Q1-Q3 2024 data releases, and the date for the Annual General Meeting (AGM). This structure—providing a brief financial snapshot and announcing the schedule for future detailed reports and meetings—is characteristic of an Earnings Release (ER) or a general corporate update that precedes formal filings. Since it provides key financial data (cash position) and announces the schedule for subsequent earnings updates (which are typically ERs), it fits best as an Earnings Release (ER) announcing preliminary results/cash position, or potentially a Report Publication Announcement (RPA) if it were only announcing the schedule. However, because it contains the actual cash position as of the end of the period, it functions as an initial results announcement. It is not a full 10-K (Annual Report) or IR (Interim Report) because it only gives the cash position and a calendar, not the full financial statements. It is not a DEF 14A (Remuneration) or DVA (Voting Results). It is not an AGM-R because it is announcing the date of the AGM, not providing AGM materials. It is not an RPA because it contains substantive financial information (cash position) rather than just announcing *when* a report will be released. Therefore, classifying it as an Earnings Release (ER) announcing preliminary results/cash position is the most appropriate fit.
2024-01-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.